Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

There is uncertainty regarding the usefulness of CDK4/6-inhibitor-based therapy for hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2−), metastatic breast cancer (MBC), when CDK4/6 inhibitor treatment had previously failed. Furthermore, a biomarker for abemacicli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yan, Lv, Meng, Wang, Yongmei, Cao, Weihong, Li, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869123/
https://www.ncbi.nlm.nih.gov/pubmed/36698413
http://dx.doi.org/10.3389/fonc.2022.1022913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869123/
https://www.ncbi.nlm.nih.gov/pubmed/36698413
http://dx.doi.org/10.3389/fonc.2022.1022913

Ejemplares similares